Recent ideas of GBS being a spectrum of nodo-paranodopathy with varying degrees of paranodal and axonal damage determining the electrophysiological phenotype may be supported by these data.21 Although almost all GBS cases in the UK are ‘demyelinating’, the data here suggest peripherin consistently rises, indicating axonal damage in most cases. The gene discussed is PRPH; the disease is Guillain-Barre syndrome.